K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

Q4 2024 Earnings Call Transcript March 5, 2025 Zymeworks Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, ...

In 2004, The Novartis Institute for Tropical Disease opened in Singapore, with a focus ... over-the-counter brand portfolio of Bristol-Myers Squibb. In 2006, Novartis announced the creation ...

From 2008 to 2017, he served as an executive director of the clinical development department at Celgene (now part of Bristol-Myers Squibb). He has been a member of the American Society of ...

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $60.18, moving +0.6% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.78%.

Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise ...

Bristol Myers Squibb stock (NYSE: BMY) has gained 7% this year, outperforming the S&P 500 which has declined 1%. BMS’s strong Q4 performance has helped drive its positive momentum. While markets ...

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company.

March 11 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will acquire 2seventy bio (TSVT.O), opens new tab for about $286 million in cash, sending the cancer cell therapy maker's shares up ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks. Stock market investors have enjoyed strong annual returns over the ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other dividend stocks. Dividend stocks have taken a backseat in the market as ...